DexCom (NASDAQ:DXCM) Issues Earnings Results, Beats Estimates By $0.09 EPS

DexCom (NASDAQ:DXCM) issued its earnings results on Thursday. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09, FiscalAI reports. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter last year, the firm earned $0.48 earnings per share. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year.

Here are the key takeaways from DexCom’s conference call:

• Positive Sentiment: Dexcom reported Q2 revenue of $1.31 billion, up 13% year over year, with international revenue rising 19%. Management raised full-year revenue guidance to $5.18–$5.25 billion and increased gross and operating margin outlooks.
• Positive Sentiment: The CONNECT trial showed a 1.6% A1C improvement among non-insulin type 2 diabetes patients, with 97% median CGM utilization. Dexcom believes the results could support broader commercial and Medicare reimbursement, including a potential CMS decision by year-end and coverage beginning in mid-2027.
• Positive Sentiment: G7 15-day adoption is tracking to plan, with nearly 50% of the U.S. customer base expected to convert by year-end. The product is now integrated with Tandem systems, has received Canadian regulatory clearance, and is contributing to stronger customer satisfaction and future margin expansion.
• Positive Sentiment: Strong execution drove non-GAAP gross margin to 64.1%, adjusted EBITDA margin to 32.2%, and more than $600 million of free cash flow in the first half. Dexcom repurchased approximately $600 million of stock in Q2 under its $1 billion 2026 authorization and completed its acquisition of Nutrisense to add personalized nutrition insights.
• Neutral Sentiment: Growth initiatives carry some near-term cost and execution considerations, including hiring and startup expenses for the Ireland manufacturing facility and approximately $15 million of second-half international revenue pressure from foreign exchange. Management expects gross margin to dip as Ireland production begins before leveraging over time.

DexCom Price Performance

DXCM stock traded up $8.06 during trading hours on Friday, hitting $82.60. 5,274,984 shares of the stock traded hands, compared to its average volume of 5,217,309. The stock has a 50-day simple moving average of $72.91 and a 200 day simple moving average of $69.10. The company has a market cap of $31.87 billion, a P/E ratio of 35.21, a P/E/G ratio of 1.24 and a beta of 1.45. DexCom has a one year low of $54.11 and a one year high of $87.00. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $74.13, for a total value of $296,520.00. Following the transaction, the director owned 52,852 shares of the company’s stock, valued at $3,917,918.76. The trade was a 7.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares in the company, valued at $7,075,708.50. The trade was a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,506 shares of company stock valued at $7,205,258 in the last quarter. 0.28% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Brighton Jones LLC grew its holdings in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of DexCom during the third quarter valued at $216,000. DRW Securities LLC acquired a new position in shares of DexCom in the 4th quarter valued at $205,000. T. Rowe Price Investment Management Inc. increased its stake in DexCom by 25.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,687 shares of the medical device company’s stock worth $179,000 after purchasing an additional 538 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in DexCom by 50.6% in the 4th quarter. Parallel Advisors LLC now owns 2,458 shares of the medical device company’s stock worth $163,000 after purchasing an additional 826 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on DXCM shares. Mizuho increased their price target on DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Bank of America cut their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Stifel Nicolaus set a $95.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Friday. Citigroup restated a “buy” rating on shares of DexCom in a research report on Friday. Finally, William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus target price of $87.25.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported adjusted earnings of $0.70 per share, versus the $0.61 analyst consensus, while revenue rose 13.1% year over year to $1.31 billion, ahead of the $1.29 billion estimate. DexCom Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, citing strong demand for glucose monitors. The company is targeting nearly 50% U.S. conversion to its G7 15 Day system by year-end. Dexcom raises annual revenue forecast
• Positive Sentiment: Growth remained broad-based. U.S. revenue increased 11% to $933 million, while international revenue growth was stronger, supporting the bullish view of DexCom’s expanding CGM platform and newer products such as G7 15 Day and Stelo. DexCom Q2 2026 earnings call highlights
• Positive Sentiment: Analyst sentiment improved after the report. Wells Fargo raised its price target to $90 from $85 and maintained an overweight rating, while Benchmark lifted its target to $82 from $77 and assigned a buy rating. UBS also reaffirmed its buy rating with a $96 target.
• Neutral Sentiment: Institutional positioning was mixed. Several major investors, including Wellington Management, AllianceBernstein and UBS, added shares, while Jennison Associates and Nuveen reduced their holdings.
• Negative Sentiment: Insider trading remains a risk signal. Company insiders reported 14 open-market sales and no purchases during the past six months, including sales by Executive Chair Kevin Sayer and other executives.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.